USPTO serial 87400539
LUMIRADX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Dec 14, 2021
- Examiner
- GOODMAN, WENDY BETH
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with LUMIRADX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $548*
Plus Government fees of $650
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Mona Gupta
Mona Gupta Roche Diagnostics Operations, Inc.9115 Hague RoadIndianapolis, IN 46250United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 010 | Diagnostic, examination and monitoring equipment, namely, equipment for detecting and monitoring chronic diseases, infectious diseases, genetic disorders and conditions, cardiovascular diseases and conditions, diabetes, cancer, pregnancy and prenatal conditions, sexually transmitted diseases, hematology, and drugs of abuse; medical instruments for use in detecting chronic diseases, infectious diseases, genetic disorders and conditions, cardiovascular diseases and conditions, diabetes, cancer, pregnancy and prenatal conditions, sexually transmitted diseases, hematology, and drugs of abuse; apparatus for analyzing substances for medical use, namely, apparatus for analyzing biological substances for the presence, absence, or quantity of target chemicals and biologics; medical diagnostic apparatus for testing glucose levels, weight, temperature, posture, sleep, stress levels, blood pressure, international normalized ratio, and vital signs and detecting chronic diseases, infectious diseases, genetic disorders and conditions, cardiovascular diseases and conditions, diabetes, cancer, pregnancy and prenatal conditions, sexually transmitted diseases, hematology, and drugs of abuse; medical apparatus for monitoring vital signs; medical apparatus for use in analyzing glucose levels, weight, temperature, posture, sleep, stress levels, blood pressure, international normalized ratio, and vital signs; automatic analyzers for testing and analysing biological substances for the presence, absence, or quantity of target chemicals and biologics for medical diagnosis; diagnostic apparatus for medical purposes; diagnostic imaging apparatus for medical use; diagnostic instruments for medical use, namely, for the testing and analysis of assays; diagnostic measuring apparatus for medical use, namely, apparatus for measuring glucose levels, weight, temperature, posture, sleep, stress levels, blood pressure, international normalized ratio, and vital signs; electromedical diagnostic instruments, namely, instruments for detecting chronic diseases, infectious diseases, genetic disorders and conditions, cardiovascular diseases and conditions, diabetes, cancer, pregnancy and prenatal conditions, sexually transmitted diseases, hematology, and drugs of abuse; electronic apparatus for medical purposes, namely, apparatus for detecting, measuring and monitoring glucose levels, weight, temperature, posture, sleep, stress levels, blood pressure, international normalized ratio, vital signs, chronic diseases, infectious diseases, genetic disorders and conditions, cardiovascular diseases and conditions, diabetes, cancer, pregnancy and prenatal conditions, sexually transmitted diseases, hematology, and drugs of abuse; electronic medical instruments used for detecting, measuring and monitoring glucose levels, weight, temperature, posture, sleep, stress levels, blood pressure, international normalized ratio, vital signs, chronic diseases, infectious diseases, genetic disorders and conditions, cardiovascular diseases and conditions, diabetes, cancer, pregnancy and prenatal conditions, sexually transmitted diseases, hematology and drugs of abuse; electronic monitoring instruments for medical use used to monitor glucose levels, weight, temperature, posture, sleep, stress levels, blood pressure, international normalized ratio, vital signs, chronic diseases, infectious diseases, genetic disorders and conditions,cardiovascular diseases and conditions, diabetes, cancer, pregnancy and prenatal conditions, sexually transmitted diseases, hematology and drugs of abuse; medical analysis instruments used for testing and analysing biological substances for the presence, absence, or quantity of target chemicals and biologics; medical apparatus and instruments used for detecting, measuring and monitoring glucose levels, weight, temperature, posture, sleep, stress levels, blood pressure, international normalized ratio, vital signs, chronic diseases, infectious diseases, genetic disorders and conditions, cardiovascular diseases and conditions, diabetes, cancer, pregnancy and prenatal conditions, sexually transmitted diseases, hematology and drugs of abuse; medical apparatus for detecting and measuring substances in the nature of target chemicals and biologics in bodily fluids; medical diagnostic apparatus used for detecting chronic diseases, infectious diseases, genetic disorders and conditions, cardiovascular diseases and conditions, diabetes, cancer, pregnancy and prenatal conditions, sexually transmitted diseases, hematology, and drugs of abuse; medical diagnostic instruments used for detecting chronic diseases, infectious diseases, genetic disorders and conditions, cardiovascular diseases and conditions, diabetes, cancer, pregnancy and prenatal conditions, sexually transmitted diseases, hematology, and drugs of abuse; medical imaging apparatus; medical testing instruments used to test glucose levels, weight, temperature, posture, sleep, stress levels, blood pressure, international normalized ratio, vital signs and detection of chronic diseases, infectious diseases, genetic disorders and conditions, cardiovascular diseases and conditions, diabetes, cancer, pregnancy and prenatal conditions, sexually transmitted diseases, hematology, and drug abuse; scanners for medical diagnosis; sensor apparatus used for sensing weight, temperature, posture, sleep, stress levels, blood pressure, international normalized ratio and vital signs for medical use in diagnosis; medical diagnostic testing instruments used for detecting chronic diseases, infectious diseases, genetic disorders and conditions, cardiovascular diseases and conditions, diabetes, cancer, pregnancy and prenatal conditions, sexually transmitted diseases, hematology, and drugs of abuse for medical diagnostic purposes; trace material analyzers for use in diagnosis of chronic diseases, infectious diseases, genetic disorders and conditions, cardiovascular diseases and conditions, diabetes, cancer, pregnancy and prenatal conditions, sexually transmitted diseases, hematology, and drug abuse | ACTIVE | — |
| 044 | Healthcare services; medical services; advisory services relating to medical apparatus and instruments for detecting, measuring and monitoring glucose levels, weight, temperature, posture, sleep, stress levels, blood pressure, international normalized ratio, vital signs, chronic diseases, infectious diseases, genetic disorders and conditions, cardiovascular diseases and conditions, diabetes, cancer, pregnancy and prenatal conditions, sexually transmitted diseases, hematology, and drugs of abuse; compilation of medical reports designed to provide patients and healthcare professionals with customized diagnostic information, patient diagnoses, medical treatment plans and healthcare management plans; consultancy and information services relating to medical products for detecting, measuring and monitoring glucose levels, weight, temperature, posture, sleep, stress levels, blood pressure, international normalized ratio, vital signs, chronic diseases, infectious diseases, genetic disorders and conditions, cardiovascular diseases and conditions, diabetes, cancer, pregnancy and prenatal conditions, sexually transmitted diseases, hematology, and drugs of abuse; consultancy services in the field of health; consultancy services relating to diagnostic preparations for medical purposes; consultancy services relating to medical diagnostic apparatus and instruments; drug, alcohol and DNA screening for medical purposes; maintaining personal medical history records and files; medical analysis services, namely, providing medical record analysis and assessment services designed to provide patients and healthcare professionals with customized diagnostic information, patient diagnoses, medical treatment plans and healthcare management plans; medical diagnostic testing services; medical health assessment services; medical information; medical information retrieval services for the purpose of providing patients and healthcare professionals with diagnostic information and patient diagnoses; medical information services; medical screening; medical diagnosis and treatment of chronic diseases, infectious diseases, genetic disorders and conditions, cardiovascular diseases and conditions, diabetes, cancer, pregnancy and prenatal conditions, sexually transmitted diseases, and drug abuse; medical testing; online health and medical services, namely, providing an interactive database for exchanging information between a medical device user and healthcare providers, delivered via a global computer network; providing news and information in the field of medicine; providing online medical record analysis services designed to provide patients with custom tailored information about the range of possible diagnosis and therapies associated with defined set of symptoms other than dentistry; rental of apparatus and installations in the field of medical technology; rental of medical and health care equipment; services for the preparation of medical reports, namely, providing patients and healthcare professionals with customized diagnostic reports, medical treatment plans and healthcare management plans; services for the provision of medical care information, namely, providing patients and healthcare professionals with customized plans for the treatment and management of chronic diseases, infectious diseases, genetic disorders and conditions, cardiovascular diseases and conditions, diabetes, cancer, pregnancy and prenatal conditions, sexually transmitted diseases, and drug abuse; telemedicine services; providing advice, consultancy and information on all of the aforesaid services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by LumiraDX International Ltd
- Other trademarks owned by LumiraDX International Ltd
- Other trademarks owned by LumiraDX International Ltd
- Other trademarks in Class 010
- Other trademarks in Class 044
- Similar marks named LUMIRADX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 13, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Sep 13, 2024 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Sep 13, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 13, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Sep 11, 2024 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Aug 16, 2024 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Dec 14, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 28, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 28, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 8, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 26, 2021 | FIXD | ELECTRONIC RECORD REVIEW COMPLETE | — |
| Aug 20, 2021 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Aug 16, 2021 | ADBS | 1(B) BASIS DELETED; NEW BASIS REQUESTED | — |
| Jun 18, 2021 | MREI | NOTICE OF REINSTATEMENT E-MAILED | — |
| Jun 14, 2021 | PCBG | PETITION TO DIRECTOR - CHANGE BASIS - GRANTED | — |
| Jun 14, 2021 | REIN | REINSTATED | — |
| Jun 14, 2021 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jun 10, 2021 | APET | ASSIGNED TO PETITION STAFF | — |
| Jun 10, 2021 | NOAC | CORRECTED NOA E-MAILED | — |
| Jun 9, 2021 | DPCC | DIVISIONAL PROCESSING COMPLETE | — |
| May 26, 2021 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Apr 12, 2021 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Apr 12, 2021 | DRRR | DIVISIONAL REQUEST RECEIVED | — |
| Apr 12, 2021 | ERTD | TEAS REQUEST TO DIVIDE RECEIVED | — |
| Apr 12, 2021 | TPDR | TEAS PETITION TO DIRECTOR RECEIVED | — |
| Apr 7, 2021 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Oct 21, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 20, 2020 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Oct 19, 2020 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Oct 9, 2020 | EXT5 | SOU EXTENSION 5 FILED | — |
| Oct 9, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 9, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 7, 2020 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Apr 7, 2020 | EXT4 | SOU EXTENSION 4 FILED | — |
| Apr 7, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 12, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 10, 2019 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Oct 10, 2019 | EXT3 | SOU EXTENSION 3 FILED | — |
| Oct 10, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 11, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 9, 2019 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Apr 9, 2019 | EXT2 | SOU EXTENSION 2 FILED | — |
| Apr 9, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 29, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 27, 2018 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Sep 27, 2018 | EXT1 | SOU EXTENSION 1 FILED | — |
| Sep 27, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 10, 2018 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Feb 13, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 13, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 24, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 27, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 27, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 27, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 27, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 28, 2017 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 28, 2017 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 28, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 28, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 13, 2017 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Apr 12, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 10, 2017 | NWAP | NEW APPLICATION ENTERED | — |